Stockscreener 앱 받기
14.80
1.45%
0.31
시간 외 거래:
14.80
Benitec Biopharma Inc 주식(BNTC)의 최신 뉴스
BenitecAnother Biopharma Rocket - Barchart
Benitec Biopharma (NASDAQ:BNTC) Shares Cross Above 50-Day Moving Average – Here’s Why - Defense World
Benitec BiopharmaGetting To The Roots Of Oculopharyngeal Muscular Dystrophy - RTTNews
Benitec Biopharma stock soars to 52-week high of $13.32 By Investing.com - Investing.com Australia
Benitec Biopharma stock soars to 52-week high of $13.32 - Investing.com India
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
How to Take Advantage of moves in (BNTC) - Stock Traders Daily
Antisense & RNAi Therapeutics Market to Set Remarkable Growth - openPR
Benitec Biopharma to Participate in Upcoming Conferences in March - GlobeNewswire
Reviewing NexImmune (NASDAQ:NEXI) & Benitec Biopharma (NASDAQ:BNTC) - Defense World
Benitec Biopharma's SWOT analysis: gene therapy stock shows promise amid trials By Investing.com - Investing.com South Africa
Benitec Biopharma’s SWOT analysis: gene therapy stock shows promise amid trials - Investing.com India
Benitec Biopharma's SWOT analysis: gene therapy stock shows promise amid trials - Investing.com
Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know - MSN
HC Wainwright Reiterates “Buy” Rating for Benitec Biopharma (NASDAQ:BNTC) - Defense World
(BNTC) Pivots Trading Plans and Risk Controls - Stock Traders Daily
H.C. Wainwright maintains $28 target on Benitec BioPharma stock By Investing.com - Investing.com UK
Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Citizens JMP maintains Benitec stock with $18 target By Investing.com - Investing.com Australia
Citizens JMP maintains Benitec stock with $18 target - Investing.com India
Benitec Biopharma (NASDAQ:BNTC) Announces Earnings Results, Beats Estimates By $0.19 EPS - MarketBeat
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Rating of “Buy” from Analysts - Defense World
Benitec Biopharma Inc. (NASDAQ:BNTC) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Benitec Biopharma (NASDAQ:BNTC) Stock Price Passes Below 50-Day Moving AverageHere's What Happened - MarketBeat
Benitec Biopharma Inc. Announces Q4 2024 Financial Results and Operational Update - Defense World
Benitec Biopharma Announces Acceptance of Late- Breaking - GlobeNewswire
Benitec presents new gene therapy data at MD conference By Investing.com - Investing.com Canada
Benitec presents new gene therapy data at MD conference - Investing.com India
Benitec Biopharma Releases Second Quarter 2025 Financial Results and Provides Operational Update - TradingView
Benitec Biopharma Inc. Announces Late-Breaking Presentation on BB-301 Phase 1b/2a Clinical Study for Oculopharyngeal Muscular Dystrophy at 2025 MDA Conference - Nasdaq
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference - The Manila Times
Benitec Biopharma Inc. (BNTC) reports earnings - Quartz
Benitec Biopharma Announces Acceptance of Late- Breaking Oral Abstract for the BB-301 Phase 1b/2a Clinical Study at the Muscular Dystrophy Association Clinical and Scientific Conference - GlobeNewswire Inc.
Benitec Biopharma Inc. SEC 10-Q Report - TradingView
(BNTC) Investment Analysis - Stock Traders Daily
Benitec Biopharma (BNTC) Expected to Announce Quarterly Earnings on Monday - Defense World
Benitec Biopharma (BNTC) Projected to Post Earnings on Monday - MarketBeat
Institutional investors are Benitec Biopharma Inc.'s (NASDAQ:BNTC) biggest bettors and were rewarded after last week's US$33m market cap gain - Simply Wall St
Benitec Biopharma (NASDAQ:BNTC) Share Price Crosses Above Fifty Day Moving AverageHere's What Happened - MarketBeat
(BNTC) Technical Pivots with Risk Controls - Stock Traders Daily
Franklin Resources Inc. Acquires Significant Stake in Benitec Bi - GuruFocus.com
Benitec Biopharma to Participate in Upcoming Conferences in January and February - GlobeNewswire
BNTCBenitec Biopharma Inc. Latest Stock News & Market Updates - StockTitan
Benitec Biopharma Announces Three Major Conference Presentations for Early 2025 - StockTitan
Guggenheim Initiates Coverage of Benitec Biopharma (BNTC) with Buy Recommendation - MSN
0.49%
1.87%
자본화:
|
볼륨(24시간):